Decoding Immunotherapy's liver side effect to keep cancer treatment on track

NCT ID NCT06864481

Recruiting now Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at liver inflammation (hepatitis) that can occur in cancer patients treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers aim to describe the different patterns of liver injury and how they respond to treatment. By collecting real-world data from 250 adult patients, the goal is to help doctors make better decisions about managing this side effect and when it might be safe to restart immunotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to better guidelines for managing liver side effects from immunotherapy and safer decisions about restarting cancer treatment.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not apply to all patients or cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer cholangitis drug-induced hepatitis drug-induced liver injury hepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER PATIENTS LIVER INJURY SECONDARY TO IMMUNE CHECKPOINT INHIBITORS

Contacts and locations

Locations

Montpellier University Hospital
RECRUITING

Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.